SK285663B6 - Spôsob prípravy mykofenolátu mofetilu - Google Patents
Spôsob prípravy mykofenolátu mofetilu Download PDFInfo
- Publication number
- SK285663B6 SK285663B6 SK1506-2003A SK15062003A SK285663B6 SK 285663 B6 SK285663 B6 SK 285663B6 SK 15062003 A SK15062003 A SK 15062003A SK 285663 B6 SK285663 B6 SK 285663B6
- Authority
- SK
- Slovakia
- Prior art keywords
- mycophenolate mofetil
- mycophenolic acid
- morpholinoethanol
- process according
- ethers
- Prior art date
Links
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 title claims abstract description 23
- 229960004866 mycophenolate mofetil Drugs 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims description 18
- 238000002360 preparation method Methods 0.000 title claims description 7
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims abstract description 16
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims abstract description 16
- 229960000951 mycophenolic acid Drugs 0.000 claims abstract description 16
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 claims abstract description 15
- 150000002170 ethers Chemical class 0.000 claims abstract description 7
- 239000002904 solvent Substances 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 238000009835 boiling Methods 0.000 claims description 7
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 230000032050 esterification Effects 0.000 claims description 5
- 238000005886 esterification reaction Methods 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 239000012442 inert solvent Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 10
- 238000000926 separation method Methods 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical group [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- -1 2-morpholinoethyl Chemical group 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- AOPDRZXCEAKHHW-UHFFFAOYSA-N 1-pentoxypentane Chemical compound CCCCCOCCCCC AOPDRZXCEAKHHW-UHFFFAOYSA-N 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
- 241000394605 Viola striata Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229950007856 mofetil Drugs 0.000 description 1
- 229940046781 other immunosuppressants in atc Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Furan Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ20012071A CZ292123B6 (cs) | 2001-06-08 | 2001-06-08 | Způsob přípravy mykofenolátu mofetilu |
| PCT/US2002/018274 WO2002100855A1 (en) | 2001-06-08 | 2002-06-08 | Method of mycophenolate mofetil preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK15062003A3 SK15062003A3 (en) | 2004-11-03 |
| SK285663B6 true SK285663B6 (sk) | 2007-05-03 |
Family
ID=5473426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1506-2003A SK285663B6 (sk) | 2001-06-08 | 2002-06-08 | Spôsob prípravy mykofenolátu mofetilu |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20050085635A1 (cs) |
| EP (1) | EP1421081A4 (cs) |
| JP (1) | JP2004534063A (cs) |
| KR (1) | KR20040030660A (cs) |
| CN (1) | CN1253450C (cs) |
| AR (1) | AR041777A1 (cs) |
| BR (1) | BR0210931A (cs) |
| CA (1) | CA2450013A1 (cs) |
| CZ (1) | CZ292123B6 (cs) |
| HU (1) | HUP0400189A3 (cs) |
| NZ (1) | NZ530013A (cs) |
| PL (1) | PL364366A1 (cs) |
| RU (1) | RU2283313C2 (cs) |
| SK (1) | SK285663B6 (cs) |
| TW (1) | TWI241299B (cs) |
| WO (1) | WO2002100855A1 (cs) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1667987T3 (pl) * | 2003-09-11 | 2009-01-30 | Sandoz Ag | Sposób wytwarzania mykofenolanu mofetylu |
| TW200613294A (en) | 2004-04-26 | 2006-05-01 | Teva Gyogyszergyar Reszvenytarsasag | Process for preparation of mycophenolic acid and ester derivatives thereof |
| WO2005105769A2 (en) | 2004-04-27 | 2005-11-10 | Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg - | Mycophenolate mofetil impurity |
| WO2006012379A2 (en) | 2004-07-20 | 2006-02-02 | Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg | Processes for preparation of crystalline mycophenolate sodium |
| ITMI20041703A1 (it) * | 2004-09-03 | 2004-12-03 | Poli Ind Chimica Spa | Metodo di preparazione del mofetil micofenolato per transesterificazione enzimatica |
| CN1328272C (zh) * | 2005-08-22 | 2007-07-25 | 鲁南制药集团股份有限公司 | 一种工业化生产霉酚酸莫啡酯的方法 |
| CN100402516C (zh) * | 2005-10-18 | 2008-07-16 | 深圳市东阳光实业发展有限公司 | 一种霉酚酸莫啡酯的制备方法 |
| EP2032712B1 (en) * | 2006-06-29 | 2010-02-10 | Ivax Pharmaceuticals S.R.O. | Regulation of acid metabolite production |
| CN1974564B (zh) * | 2006-12-15 | 2010-05-12 | 丽珠集团新北江制药股份有限公司 | 一种霉酚酸莫啡酯的制备方法 |
| US20080188653A1 (en) | 2007-02-04 | 2008-08-07 | Formosa Laboratories, Inc. | Process for Preparation of Mycophenolate Mofetil |
| CN100484930C (zh) * | 2007-03-16 | 2009-05-06 | 重庆大新药业股份有限公司 | 一种吗替麦考酚酯的制备方法 |
| EP2024506A1 (en) * | 2007-04-11 | 2009-02-18 | Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság | Method for reducing impurity level in mycophenolic acid fermentation |
| WO2009000834A1 (en) * | 2007-06-27 | 2008-12-31 | Dsm Ip Assets B.V. | Method for the purification of mycophenolate mofetil |
| WO2009003878A1 (en) * | 2007-06-29 | 2009-01-08 | Dsm Ip Assets B.V. | Method for the preparation of mycophenolate mofetil |
| WO2009010503A1 (en) * | 2007-07-18 | 2009-01-22 | Dsm Ip Assets B.V. | Mycophenolic acid recycling in a method for the preparation of mycophenolate mofetil |
| CN101671706B (zh) * | 2009-09-05 | 2013-09-18 | 山东新时代药业有限公司 | 一种霉酚酸发酵过程中补糖方法 |
| CN103265514B (zh) * | 2013-06-08 | 2016-01-13 | 重庆理工大学 | 一种制备吗替麦考酚酯的方法 |
| CN107056736A (zh) * | 2017-05-08 | 2017-08-18 | 福建省微生物研究所 | 一种吗替麦考酚酯的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4748173A (en) * | 1987-01-30 | 1988-05-31 | Syntex (U.S.A.) Inc. | Heterocyclic aminoalkyl esters of mycophenolic acid and derivatives thereof and pharmaceutical compositions |
| HU203678B (en) * | 1988-09-26 | 1991-09-30 | Richter Gedeon Vegyeszet | Method for increased dewatering condensation reaction mixtures |
| US5247083A (en) * | 1992-07-10 | 1993-09-21 | Syntex (U.S.A.) Inc. | Direct esterification of mycophenolic acid |
| RO118075B1 (ro) * | 1993-09-15 | 2003-01-30 | Syntex Inc | Sare de micofenolat de mofetil, compozitie farmaceutica care o contine si formulare intravenoasa |
-
2001
- 2001-06-08 CZ CZ20012071A patent/CZ292123B6/cs not_active IP Right Cessation
-
2002
- 2002-06-07 TW TW091112451A patent/TWI241299B/zh not_active IP Right Cessation
- 2002-06-07 AR ARP020102144A patent/AR041777A1/es not_active Application Discontinuation
- 2002-06-08 JP JP2003503622A patent/JP2004534063A/ja active Pending
- 2002-06-08 US US10/480,058 patent/US20050085635A1/en not_active Abandoned
- 2002-06-08 RU RU2004100227/04A patent/RU2283313C2/ru not_active IP Right Cessation
- 2002-06-08 PL PL02364366A patent/PL364366A1/xx unknown
- 2002-06-08 NZ NZ530013A patent/NZ530013A/en unknown
- 2002-06-08 WO PCT/US2002/018274 patent/WO2002100855A1/en active IP Right Grant
- 2002-06-08 BR BR0210931-0A patent/BR0210931A/pt not_active IP Right Cessation
- 2002-06-08 SK SK1506-2003A patent/SK285663B6/sk unknown
- 2002-06-08 HU HU0400189A patent/HUP0400189A3/hu unknown
- 2002-06-08 KR KR10-2003-7016069A patent/KR20040030660A/ko not_active Ceased
- 2002-06-08 CA CA002450013A patent/CA2450013A1/en not_active Abandoned
- 2002-06-08 CN CNB028126998A patent/CN1253450C/zh not_active Expired - Fee Related
- 2002-06-08 EP EP02756146A patent/EP1421081A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AR041777A1 (es) | 2005-06-01 |
| KR20040030660A (ko) | 2004-04-09 |
| SK15062003A3 (en) | 2004-11-03 |
| CN1253450C (zh) | 2006-04-26 |
| BR0210931A (pt) | 2004-06-08 |
| CA2450013A1 (en) | 2002-12-19 |
| HUP0400189A2 (hu) | 2004-07-28 |
| HUP0400189A3 (en) | 2007-05-29 |
| EP1421081A1 (en) | 2004-05-26 |
| JP2004534063A (ja) | 2004-11-11 |
| NZ530013A (en) | 2005-05-27 |
| WO2002100855A1 (en) | 2002-12-19 |
| CZ292123B6 (cs) | 2003-08-13 |
| PL364366A1 (en) | 2004-12-13 |
| CN1520411A (zh) | 2004-08-11 |
| CZ20012071A3 (cs) | 2003-01-15 |
| RU2004100227A (ru) | 2005-06-27 |
| US20050085635A1 (en) | 2005-04-21 |
| EP1421081A4 (en) | 2004-11-03 |
| HK1068630A1 (en) | 2005-04-29 |
| TWI241299B (en) | 2005-10-11 |
| RU2283313C2 (ru) | 2006-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK285663B6 (sk) | Spôsob prípravy mykofenolátu mofetilu | |
| US20030225075A1 (en) | Novel pyrimidone derivatives | |
| JP2667987B2 (ja) | ５−［２−（４−（ベンゾイソチアゾール−３−イル）−ピペラジン−１−イル）エチル］−６−クロロ−１，３−ジヒドロ−インドール−２−オンの製造方法及び製造用中間体 | |
| JPS63139182A (ja) | チアゾリジンジオン誘導体の製造法 | |
| US4683234A (en) | 2,6-Dimethyl-3N,5-disubstituted-4-(substituted phenyl)3,4-dihydropyrimidine compounds and a method for treating disorders of cardiocircular system | |
| FR2846657A1 (fr) | Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| EP1982983B1 (en) | Improved process for producing moxonidine | |
| SK3092003A3 (en) | Process for the preparation of mesylates of piperazine derivatives | |
| EP0348257A2 (fr) | Nouveaux dérivés d'(hétéro)aryl diazole, leur procédé de préparation et leur application en thérapeutique | |
| CA1336516C (en) | Acyl derivatives of 2-amino-4-substituted-5-hydroxy pyrimidines | |
| JP4908706B2 (ja) | ベンゾフラン誘導体 | |
| HU217981B (hu) | N-(3-klór-fenil)-piperazin-származékok és eljárás ezek előállítására | |
| JP3136609B2 (ja) | Ｎ−シアノイミノ複素環式化合物 | |
| US4482561A (en) | Therapeutically effective piperidyl N-(4-quinolyl)-anthraniloyloxyalkanoates | |
| JP4110633B2 (ja) | ３−アミノ−４−フルオロ−２−不飽和カルボン酸エステル及びその製法 | |
| KR100426534B1 (ko) | 아젤라스틴의 개선된 합성방법 | |
| CZ2005431A3 (cs) | Zpusob prípravy mykofenolátu mofetilu | |
| FR2790472A1 (fr) | Derives de cyclobutene-3, 4-dione, leur preparation et leur application en therapeutique | |
| US7619084B2 (en) | Process for preparing 4-aminopyrimidine compound | |
| JPH0550495B2 (cs) | ||
| JP4123609B2 (ja) | ６−（α−フルオロアルキル）−４−ピリミドンの製造方法 | |
| JPH035466A (ja) | フェノキシエチルアミノピリミジン誘導体の製造法 | |
| JPH1112254A (ja) | ３−（３−ピリジルメチルアミノ）−３，４−ジヒドロ−２（１ｈ）−キナゾリノン誘導体及びその中間体の製造方法 | |
| JPH0368546A (ja) | 置換グリシン誘導体の製造方法 | |
| JP2001278865A (ja) | ４−アミノキノリン類の製造方法 |